Friday, July 10, 2026

pharma · Diabetes · Congenital Bleeding Disorder

Novo Nordisk A/S

Novo Nordisk is a pharma organization headquartered in bagsværd, DK. Primary therapeutic focus areas include Diabetes, Congenital Bleeding Disorder, Acquired Bleeding Disorder, Overweight, Cardiorespiratory arrest at bir

Novo Alle, Bagsværd, 2880, DK HQ
1923 Founded
63,033 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Novo Alle, Bagsværd, 2880, DK
Founded
1923
Employees
63,033
Programs
40
Drugs
46
Patents
0
Clinical program

Matched Placebo

Phase 2 · small molecule · Mechanical allodynia

Matched Placebo for Mechanical allodynia is a Phase 2 program (small_molecule) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).

← All Novo Nordisk A/S projects Phase 2 small molecule active

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Novo Nordisk A/S
Phase
Phase 2
Modality
small_molecule
Indication
Mechanical allodynia
Status
active
Trials
1

Clinical trials